Skip to main content
$9.58 -$0.31 (-3.1%)

04:00 PM EST on 03/04/24

Bausch Health Companies Inc. (NYSE:BHC)

CAPS Rating: 2 out of 5

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Current Price $9.58 Mkt Cap $3.5B
Open $9.79 P/E Ratio -5.90
Prev. Close $9.58 Div. (Yield) $0.00 (0.0%)
Daily Range $9.48 - $9.88 Volume 2,860,876
52-Wk Range $5.57 - $10.15 Avg. Daily Vol. 2,377,214


How do you think NYSE:BHC will perform against the market?

Add Stock to CAPS Watchlist

All Players

429 Outperform
61 Underperform

All-Star Players

58 Outperform
11 Underperform

Wall Street

0 Outperform
0 Underperform

Top NYSE:BHC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

jamiebjr (91.28)
Submitted September 06, 2016

The C suite has been cleared. Even if lawsuits are pending, the present Valeant is full of new life and ready for a new chapter. From the Bottom Up!

LurkyLurky (99.11)
Submitted February 06, 2018

Scam pharmaceutical company, does no R&D, buys other drug companies and jacks up the price of the medicine.

Recent Community Commentary

Read the most recent pitches from players about BHC.


Member Avatar Bigsef77 (53.48) Submitted: 2/5/2019 1:02:12 PM : Outperform Start Price: $13.42 NYSE:BHC Score: -139.42

Bausch (BHC) Upgraded to Strong Buy: Here's Why

Zacks Equity Research February 05, 2019


Trades from $1
Hide Full Article

Bausch Health (BHC - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

As such, the Zacks rating upgrade for Bausch is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Bausch imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate Revisions

As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.

Earnings Estimate Revisions for Bausch

For the fiscal year ending December 2018, this drugmaker is expected to earn $3.81 per share, which is a change of -0.5% from the year-ago reported number.

Analysts have been steadily raising their estimates for Bausch. Over the past three months, the Zacks Consensus Estimate for the company has increased 2.9%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.


Member Avatar LurkyLurky (99.11) Submitted: 2/6/2018 12:24:03 AM : Underperform Start Price: $16.86 NYSE:BHC Score: +140.03

Scam pharmaceutical company, does no R&D, buys other drug companies and jacks up the price of the medicine.


Member Avatar poorresults (< 20) Submitted: 10/27/2017 1:43:38 PM : Underperform Start Price: $11.39 NYSE:BHC Score: +114.44

They've had time to correct their mistakes, but can't seem to get the job done. Perhaps they have poor leadership and need to clean house ??


Find the members with the highest scoring picks in BHC.

Score Leader


expatriot08 (< 20) Score: +1,139.70

The Score Leader is the player with the highest score across all their picks in BHC.

Member Name Member
Call Time
Score Commentary
BuyTheDip 27.14 10/2/2009 Underperform 3W $10.66 -9.73% +402.18% +411.91 0 Comment
TrackDuality < 20 11/6/2009 Underperform 5Y $12.69 -24.20% +382.12% +406.32 0 Comment
39272x4 23.35 11/9/2009 Underperform 5Y $13.04 -26.24% +374.57% +400.81 0 Comment
ZeroDotCom 27.61 10/15/2009 Underperform 5Y $12.40 -22.40% +370.95% +393.35 0 Comment
FigginsCapital 70.08 12/29/2011 Underperform 5Y $45.96 -79.07% +307.40% +386.47 0 Comment
ritchey007 32.21 10/6/2008 Underperform 3M $7.63 +26.05% +390.53% +364.47 0 Comment
MrOneHundred 29.43 11/19/2012 Underperform NS $55.48 -82.66% +271.50% +354.16 0 Comment
SX3Report 65.75 8/14/2012 9/13/2012 Underperform 3M $50.94 -81.12% +263.26% +344.37 0 Comment
RafaelCanadaRed 88.96 5/7/2013 Underperform 5Y $73.43 -86.90% +215.98% +302.88 0 Comment
beat100market 32.72 7/18/2008 Underperform 3W $6.92 +39.04% +320.14% +281.11 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BHC.